Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets, and subject to the renewal of certain legislation, two programs potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to accelerating promising health innovations with two existing programs focused on immune health and precision health, announced that Appili Therapeutics Inc. (TSX:APLI, OTC:APLIF) ("Appili") has commenced the mailing of its management information circular in connection with the upcoming special meeting of their shareholders, which will b

Aditxt, Inc. ("Aditxt" "Company") (NASDAQ:ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, October 11, 2024, at 11:30 AM EDT. This update aims to connect with our stakeholders, including investors and the public, offering insights into the Company's latest developments and will address pre-submitted questions. This week's session will cover: Aditxt Overview and Transaction Updates: An update on the Company's current position and progress regarding the Evofem and Appili transactions. Overview of Aditxt's Current Programs: Updates on Aditxt's two ongoing progra

Aditxt, Inc. ("Aditxt" ) (NASDAQ:ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM), a pioneer in women's health, today announced the completion of the Third Parent Equity Investment under the Amended and Restated Merger Agreement, as amended (the "Agreement"). This investment further strengthens the strategic and collaborative relationship between the two companies as they jointly seek to expand access to healthcare solutions for women globally. Aditxt completed the Third Parent Equity Investment under the Agreement by purchasing 460 shares of Evofem Series F-1 Convertible Preferred Stock ("Evofem Pref

Acquisition target Evofem reported revenue of $7.8 million for the six months ended June 30, 2024 Acquisition target Appili has received approximately $6.0 million of the total $14.0 million to date in a non-dilutive funding commitment from DoD Shelf registration statement and resale registration statement for Equity Line of Credit declared Effective by the SEC Effected a 1-for-40 reverse split of its common stock, which was primarily intended to regain compliance with Nasdaq's minimum bid price requirement Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, announced today that it will effect a 1-for-40 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on October 2, 2024, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the annual meeting held on August 7, 2024, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025703. As a result

Companies Targeting Closing in Fourth Quarter of 2024 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM), today filed a preliminary proxy to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the "Merger Agreement"), with Aditxt and Adifem, Inc., a wholly-owned subsidiary of Aditxt ("Adifem"), pursuant to which, and on the terms and subject to the conditions thereof, Adifem will merge with and into Evofem, with Evofem surviving as a whol

Endometriosis Affects Approximately 190 Million Women Worldwide Non-invasive MET™ Diagnostic Test for Endometriosis Leverages Novel Biomarker: A Specific Deletion in Mitochondrial DNA Pearsanta's MET is Seeking to Become the First and Only Validated and Commercialized Blood-based Biomarker Test for Endometriosis Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its majority-owned subsidiary, Pearsanta, Inc. ("Pearsanta"), has entered into a Market Development Collaboration Agreement (the "Agreement") with women's health pioneer Evofem Biosciences, Inc. ("Evofem") (OTCQB:EVFM) focused

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating health innovations, and women's health pioneer, Evofem Biosciences, Inc. (OTCQB:EVFM) ("Evofem") today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the "Second Amendment"), under which Aditxt intends to acquire Evofem. Under the Second Amendment, the parties have extended the dates by which Aditxt shall complete the remaining $3 million in funding to Evofem through the purchase of 3,000 shares of Evofem's F-1 Preferred Stock. Aditxt will provide $1.5 million of financing by September 30, 2024, and an additional $1.5 mill

Prostate Cancer Diagnostic Market: Expected Growth from $6.2 Billion in 2023 to $11.5 Billion by 2032 Amid Rising Demand for Early Detection Technologies Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has submitted a grant application to the Prostate Cancer Research Program (PCRP) under the Department of Defense (DoD) Implementation Science Award funding mechanism seeking $2 million in funding. This non-dilutive funding initiative aims to advance the early detection and management of prostate cancer, a disease that remains one of the most preval

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024. Amro Albanna, Aditxt's Co-Founder, Chairman, and Chief Executive Officer, will present a corporate overview on-demand starting Monday, September 9th, at 7:00 a.m. (ET) through the conference platform. In addition to the virtual presentation, Amro Albanna will be available for one

Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review VouchersAditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and its wholly-owned subsidiary, Adivir, Inc., have entered into a second Amending Agreement (the "Amending Agreement") with Appili Therapeutics Inc. ("Appili") (TSX:APLI, OTC:APLIF), a biopharmaceutical company developing treatments and vaccines for infectious diseases and medical countermeasures.

Shares of Domino’s Pizza, Inc. (NYSE:DPZ) fell sharply during Thursday's session after the company reported mixed quarterly results. The company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion. The company is temporarily suspending its guidance metric of 1,100+ global net stores growth until the full effect of DPE's store opens and closures on international net store growth are known. Domino’s Pizza shares dipped 11.2% to $420.36 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Onconetix, Inc. (NASDAQ:ONCO) climbed 97.6% to $0.2944. On July 15, Oncon

Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY) rose sharply in today's pre-market trading after the company and Darden Restaurants, Inc. (NYSE:DRI) jointly announced that Darden will acquire Chuy's Holdings. Chuy's Holdings and Darden entered into a definitive agreement in which Darden will acquire all of Chuy's outstanding stock for $37.50 per share in cash. The all-cash transaction has an enterprise value of approximately $605 million. Chuy’s Holdings shares jumped 47.4% to $37.27 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Onconetix, Inc. (NASDAQ:ONCO) gained 65% to $0.2458 in pre-market trading. On July 15, Onconetix announced cl

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling over 1% on Wednesday. The Dow traded up 0.53% to 41,173.41 while the NASDAQ fell 2.51% to 18,044.33. The S&P 500 also fell, dropping, 1.24% to 5,597.06. Check This Out: Amazon To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday Leading and Lagging SectorsConsumer staples shares jumped by 1.4% on Wednesday. In trading on Wednesday, information technology shares fell by 3.6%. Top Headline Synchrony Financial (NYSE:SYF) reported better-than-expected second-quarter results on Wednesday. The company posted quarterly net interest income of $4.405 billion, beating the consensus of $4.28

Aditxt (NASDAQ:ADTX) stock is trading higher on Wednesday. The biotechnology company and Evofem amended and restated their merger agreement. The Details: The amended merger agreement addresses several issues, including resolving Evofem’s interim financing needs and substituting cash for Aditxt’s common stock as the consideration for Evofem’s stock. Recently, Evofem announced the acquisition of the pharmaceutical drug SOLOSEC. “We [Aditxt] believe that SOLOSEC is a valuable asset that diversifies Evofem’s portfolio and has the potential to accelerate its evolution into a dynamic global women’s health business that addresses significant health challenges”, said Amro Albann, CEO of Aditxt

Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 200 points on Wednesday. The Dow traded up 0.50% to 41,160.40 while the NASDAQ fell 2.46% to 18,053.81. The S&P 500 also fell, dropping, 1.15% to 5,601.75. Check This Out: Amazon To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday Leading and Lagging SectorsReal estate shares jumped by 1% on Wednesday. In trading on Wednesday, information technology shares fell by 3.2%. Top Headline U.S. crude oil inventories declined by 4.87 million barrels in the week ended July 12, falling for the third consecutive week, the EIA said. Equities Trading UP                       

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling around 300 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.10% to 40,914.80 while the NASDAQ fell 1.63% to 18,208.05. The S&P 500 also fell, dropping, 0.98% to 5,611.77                                 . Check This Out: Amazon To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday Leading and Lagging SectorsEnergy shares jumped by 0.5% on Wednesday. In trading on Wednesday, information technology shares fell by 2.3%. Top Headline Johnson & Johnson (NYSE:JNJ) reported better-than-expected second-quarter earnings on Wednesday. The company posted a

This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substituting cash for Aditxt's common stock as the consideration for Evofem's common stock in the merger and additional changes relating to it. Aditxt and Evofem are diligently working to close the contemplated transaction in the second half of 2024. The closing of the transaction between Aditxt and Evofem remains subject to the successful satisfaction of a number of closing conditions, including, but not limited to, Aditxt securin

— Improved loss from operations by 81% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged ex-U.S. commercial agreement for Phexxi in Middle East — SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the second quarter and first half of 2024. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. ("Aditxt") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.'s ("Evofem") (OTCQB:EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem's future success, including interim financing needs. The other revisions to the Merger Agreement, alongside additional interim financing for Evofem, include substit

SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending

-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the most favorable ratio since the Phexxi launch -- SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofe

This strategic acquisition positions Pearsanta for robust growth: expanding opportunities in women's health, spanning endometriosis to ovarian cancer, and in men's health starting with prostate cancer Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired MDNA Life Sciences Inc.'s ("MDNA") proprietary, early disease and cancer detection platform. This strategic move reinforces Pearsanta's dedication to enhancing patient outcomes through early disease detection and the power of precision diagnostics. Th

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

3 - Aditxt, Inc. (0001726711) (Issuer)

4 - Aditxt, Inc. (0001726711) (Issuer)

8-K - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

424B5 - Aditxt, Inc. (0001726711) (Filer)

424B3 - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

424B3 - Aditxt, Inc. (0001726711) (Filer)

EFFECT - Aditxt, Inc. (0001726711) (Filer)

S-1/A - Aditxt, Inc. (0001726711) (Filer)

8-K - Aditxt, Inc. (0001726711) (Filer)

Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company's wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie's appointment is intended to accelerate the commercial launch of Test2Treat.me. Test2Treat.me is an end-to-end, business-to-business ("B2B") and direct-to-consumer ("DTC") clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. "Naming Ernie as

AditxtScore™ continued driving revenue growth in 2022 by adding to its expanding customer base of large physician networks, healthcare systems, independent laboratories, and employer-sponsored programs. Aditxt, Inc., (NASDAQ:ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based wholly- owned subsidiary, Pearsanta, Inc. ("Pearsanta"), to accelerate the growth of Aditxt's second program, AditxtScore™, through future strategic revenue and growth-oriented transactions. Anthony Voorhies, currently the head of the AditxtScore™ division, will s

Completion of GMP Drug Substances in January for Clinical Trials in H2, 2023 Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request approval for Adimune™ to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023. A second study is also planned for ty

Aditxt, Inc. ("Aditxt, or the "Company"). (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced key executive management changes to support its growth plans. Corinne Pankovcin, who has served as CFO of Aditxt, has been appointed as President and will work closely with the Company's CEO, Amro Albanna, to execute Aditxt's business strategy. Thomas J. Farley, who has served as Controller and Principal Accounting Officer of Aditxt, has been appointed as CFO. As CFO of Aditxt since July 2020, Ms. Pankovcin, along with the Company's CEO and executive team, has effectively managed the Company's growth as it became publicly traded on

As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development Aditx Therapeutics, Inc. ("Aditxt") (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director. "As a new independent director of Aditxt's board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals," said Amro Albanna, co-founder and CEO of Aditxt. "We look forward to working with Dr. Chung as we establish our portfolio of fi

Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program Mountain View, CA, Jan. 29, 2021 (GLOBE NEWSWIRE) --  via NewMediaWire-- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. In this role, Dr. Tyan will be overseeing Aditxt’s therapeutic program for organ rejection including advancing current candidates towards clinical trials and developing new products for new applica